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illiam Sanders, MD,† Kelley P. Anderson, MD,‡ Alan Dyer, PHD,* Jeffrey Goldberger, MD,*
oseph Levine, MD§
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OBJECTIVES This study sought to determine whether the time from diagnosis to randomization was
related to outcome in a clinical trial of implantable cardioverter-defibrillator (ICD) insertion
in nonischemic cardiomyopathy.
BACKGROUND Whether the duration of nonischemic cardiomyopathy is related to arrhythmic risk and the
possible benefit of ICD insertion is unknown.
METHODS The Defibrillators in Nonischemic Cardiomyopathy Treatment Evaluation (DEFINITE)
trial randomized 458 patients with nonischemic dilated cardiomyopathy and a left ventricular
ejection fraction36% to receive standard medical therapy with or without an ICD. Patients
were randomized regardless of the duration of known cardiomyopathy as long as a reversible
cause of left ventricular dysfunction was not present. Patients were divided into recently and
remotely diagnosed nonischemic cardiomyopathy groups based on the time from diagnosis of
cardiomyopathy to randomization. To categorize patients, cut points of three and nine
months were used.
RESULTS Patients with recently diagnosed cardiomyopathy who received an ICD had better survival
than those treated with standard therapy at both cut points. This difference in survival was
significant at three months (p  0.05) and was borderline significant at nine months (p 
0.058). Patients with remotely diagnosed cardiomyopathy did not have a significant survival
benefit with ICD insertion, but there were no significant differences between ICD benefit in
the recent and remote diagnosis groups (p  0.17 and 0.25).
CONCLUSIONS Patients who have a recent cardiomyopathy diagnosis do not have any less ICD benefit than
those with a remote diagnosis. Thus, ICD therapy should be considered in such patients as
soon as they are identified as long as a reversible cause of left ventricular dysfunction is
excluded. (J Am Coll Cardiol 2006;47:2477–82) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.11.090Cardiology Foundation
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patients with nonischemic dilated cardiomyopathy (NIDCM)
ave a heterogeneous group of disorders contributing to left
entricular dysfunction (1). The time course of progression of
eft ventricular dysfunction is variable, and the risk factors for
udden and nonsudden death may differ over time in patients
ith different etiologies of NIDCM (2,3). The Defibrillators
n Nonischemic Cardiomyopathy Treatment Evaluation
DEFINITE) trial randomized patients with nonischemic
ilated cardiomyopathy, New York Heart Association
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hicago, Illinois; †University of North Carolina, Chapel Hill, North Carolina;
Marshfield Clinic, Marshfield, Wisconsin; and the §Heart Center, St. Francis
ospital, Roslyn, New York. Dr. Kadish has grant support from Guidant,
edtronic, and St. Jude’s, and has also been a speaker for St. Jude’s and Medtronic.
r. Dyer has grant support from St. Jude. Dr. Sanders has served as a periodic
onsultant and lecturer for all major device manufacturing companies, including
edtronic, St. Jude, Guidant, and Biotronik; in the last 5 years he has participated in
ndustry-sponsored national trials, including MADIT II, DEFINITE, COMPAN-
ON, RHYTHM, and MADIT CRT. Dr. Goldberger has grant support through
linical trials from Guidant, Medtronic, and St. Jude; he has also been a speaker for
hese same companies. Dr. Anderson has no active conflicts of interest; in the past she
as had research support from St. Jude, Medtronic, and Guidant, and she was a
peaker for Guidant over five years ago.d
Manuscript received August 10, 2005; revised manuscript received October 12,
005, accepted November 8, 2005.NYHA) heart failure class I to III, left ventricular ejection
raction 0.35, and documented ambient ventricular arrhyth-
ia to receive standard medical therapy or standard medical
herapy plus an implantable cardioverter-defibrillator (ICD)
4). No specific duration of NIDCM was required before
andomization in the DEFINITE trial, but physicians were
sked to exclude patients in whom a reversible cause of left
entricular dysfunction was present. Recently, the Center for
edical Services approved ICD insertion for patients
ho had NIDCM of at least nine months in duration (5,6).
See page 2483
atients with NIDCM of three to nine months in duration
ay undergo ICD insertion if they are enrolled in a registry.
atients within three months of diagnosis do not qualify for
CD insertion. This recommendation was not based on the
udden Cardiac Death in Heart Failure Trial (SCD-HeFT)
r the DEFINITE trial inclusion criteria (4,7,8). Whether
he duration of nonischemic cardiomyopathy is related to
ossible ICD benefit is unknown. The purpose of the
resent study was to determine whether the time from
iagnosis of cardiomyopathy to randomization is related to
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ICD After Nonischemic Cardiomyopathy Diagnosis June 20, 2006:2477–82rognosis and to estimate the degree of ICD benefit that
atients receive using a post-hoc analysis of the DEFINITE
rial data.
ETHODS
he DEFINITE trial randomized 458 patients with non-
schemic dilated cardiomyopathy to one of two groups:
) standard medical therapy and 2) standard medical ther-
py plus a single-chamber ICD. Details of the overall trial
ave been previously published (4). Briefly, over 85% of
atients in the trial were treated with beta-blockers and
ngiotensin-converting enzyme inhibitors or angiotensin
eceptor blockers. The mean left ventricular ejection frac-
ion was 0.21, and the mean age was 60 years. Patients
andomized to the ICD had a 35% decrease in all-cause
ortality—a difference that did not reach significance (p 
.08). A significant reduction (80%) in sudden arrhythmic
ardiac death was noted (p  0.05). The DEFINITE trial
rotocol did not specify criteria for a minimum length of
ime from diagnosis of nonischemic cardiomyopathy to
andomization. Physicians were instructed not to randomize
atients if there was a reversible cause of cardiomyopathy,
uch as peripartum cardiomyopathy, myocarditis, or acute
rug-induced cardiomyopathy. However, patients were ran-
omized regardless of the duration of known cardiomyop-
thy as long as the treating physician did not think that a
eversible cause of left ventricular dysfunction was present.
he time from diagnosis of cardiomyopathy to randomiza-
ion was reported to the nearest month. Most patients (n 
50; 76%) were classified as having idiopathic NIDCM.
he number of patients with different etiologies of cardio-
yopathy was too small to allow analysis of interactions
etween cause of cardiomyopathy and outcome.
tatistical methods. All 458 DEFINITE trial patients
ere stratified based on how long they had had the
IDCM diagnosis at the time of randomization. Three-
nd nine-month cut points were used for stratification.
aseline characteristics of the patients with shorter and
onger NIDCM duration were compared using two-sample
tests for continuous variables and chi-square tests for
ategorical variables with one exception. Duration of
IDCM diagnosis at the time of randomization, although
continuous variable, was highly skewed toward longer time
Abbreviations and Acronyms
CI  confidence interval
DEFINITE  Defibrillators in Nonischemic
Cardiomyopathy Treatment Evaluation
HR  hazard ratio
ICD  implantable cardioverter-defibrillator
NIDCM  nonischemic dilated cardiomyopathy
NYHA  New York Heart Association
SCD-HeFT  Sudden Cardiac Death in Heart Failure
Trialrom diagnosis to randomization. Therefore, the nonpara- detric Wilcoxon rank-sum test was used to examine differ-
nces between treatment arms on this variable.
Kaplan-Meier survival curves were constructed and com-
ared using the log-rank test. The Cox proportional hazards
odel was used to test and compare the impact of treatment
ssignment in recent and remote NIDCM duration strata
t both cut points. The differences in all-cause mortality
etween recently and remotely diagnosed patients at both
ut points were compared first. Subsequently, control for
reatment assignment was implemented by adding this
ariable as a second predictor. Finally, an interaction term
etween NIDCM duration and treatment assignment was
ntroduced to test for the difference between standard/ICD
azard ratios in recent and remote subgroups. The final
odel using the three predictors was further adjusted for the
atient’s NYHA functional class, white race, diabetes, and
RS duration. This dichotomized analysis was not pre-
pecified in the initial protocol, and this article presents a
ost-hoc analysis. Variables used in adjustment were those
hat were different between treatment arms for patients in
trata with recent or remote NIDCM diagnoses. A critical
value of 0.05 was used for all tests. The effect of treatment
ssignment on arrhythmic mortality for recently and re-
otely diagnosed patients was not tested because of a low
umber of events in the subgroups.
ESULTS
he mean time from diagnosis of cardiomyopathy to
andomization was 2.9  4 years. The range was from 1
onth to 38.5 years (median 1 year, interquartile range 2
onths to 4.6 years). There was a difference in time from
iagnosis of cardiomyopathy to randomization between the
CD and standard therapy groups. As a rule, standard
herapy patients were diagnosed more remotely (medians 20
nd 8 months, respectively; p  0.032 based on the
ilcoxon rank-sum test).
Patients were divided into recently and remotely diag-
osed nonischemic cardiomyopathy based on the time from
nitial diagnosis of cardiomyopathy to randomization using
ut points of three and nine months. Table 1 shows
emographic characteristics of patients with recently diag-
osed and remotely diagnosed cardiomyopathy for cut
oints of three and nine months. There were significant
ifferences between patients with recently and remotely
iagnosed cardiomyopathy in race, QRS duration, NYHA
unctional classification, and in the presence of diabetes
Table 1). Not surprisingly, those patients with more
emotely diagnosed cardiomyopathy had a longer QRS
uration, more severe heart failure, and a higher preva-
ence of diabetes than those with recently diagnosed
ardiomyopathy.
Overall, survival was similar in patients with recently and
emotely diagnosed cardiomyopathy. When a cut point of
hree months was used, 10.2% of patients with recently
iagnosed cardiomyopathy were deceased at 2.5 years, as
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June 20, 2006:2477–82 ICD After Nonischemic Cardiomyopathy Diagnosispposed to 16.0% of patients in remotely diagnosed group
hazard ratio [HR] 1.41; 95% confidence interval [CI] 0.82
o 2.41; p  0.22). When a cut point of 9 months was used,
1.2% of patients with recently diagnosed cardiomyopathy
ere deceased at 2.5 years, as opposed to 16.8% of those
ith remotely diagnosed cardiomyopathy (HR 1.38; 95%
I 0.850 to 2.24; p  0.194). Once assignment to ICD or
tandard therapy was controlled for in the entire sample,
here was also no difference in overall survival between the
ecently and remotely diagnosed groups (HR 1.36; 95% CI
.79 to 2.34; and HR 1.32; 95% CI 0.81 to 2.15 at three-
nd nine-month cut points; p  0.26 at both cut points).
inally, when patients treated with standard therapy were
onsidered alone, there was no difference in overall survival
etween the recently and remotely diagnosed patients (HR
.00; 95% CI 0.51 to 1.96; p  1.00 and HR 1.04; 95% CI
.55 to 1.95; p  0.91 for three- and nine-month cut
oints).
The ICD insertion was associated with a reduced risk of
eath for patients who had been diagnosed shortly before
heir enrollment in the study (Table 2, Figs. 1 and 2). A
ignificant difference was found between treatment arms in
atients with recently diagnosed cardiomyopathy when a cut
oint of three months was used (HR 0.37; 95% CI 0.14 to
.998; p  0.049) and the difference at nine months was
able 1. Demographic Characteristics of Patients With Recently
ut Points
<3 Mo; n  150 >3
n % n
CD group 82 54.7 147
ender, male 109 72.7 217
ace, white 112 74.7 197*
istory of AF 31 20.7 81
YHA functional class I 36 24.0 63
YHA functional class II 87 58.0 176
YHA functional class III 27 18.0 69
iabetes 20 13.3 85*
ypertension 12 8.0 37
eta-blocker 128 85.3 260
CE/ARB 142 94.7 291
Mean SD Mean
ge (yrs) 58.2 13.2 58.3
RS (ms) 109.4 27.4 117.9*
VEF (%) 20.9 5.7 21.6
p  0.050, difference between recently and remotely diagnosed patients.
ACE angiotensin-converting enzyme; AF atrial fibrillation; ARB angioten
jection fraction; NYHA  New York Heart Association; SD  standard deviation
able 2. All-Cause Mortality of Patients With Recently and Rem
Deaths
<3 Mo; n  150 >3 Mo;
n % n
ll patients 18/150 12.0 50/308
tandard therapy 12/68 17.6 28/161
CD 6/82* 7.3 22/147p  0.05; rates in standard therapy and ICD groups are significantly different by Cox reg
Abbreviations as in Table 1.orderline significant (HR 0.48; 95% CI 0.23 to 1.025; p 
.058) for these patients. The ICD insertion was not
ignificantly related to survival for patients who had been
iagnosed with NIDCM for longer periods of time (HR
.82; 95% CI 0.47 to 1.43; p  0.48 and HR 0.86; 95% CI
.46 to 1.94; p 0.64 at three- and nine-month cut points).
espite the fact that treatment assignment was significantly
elated to improved survival in patients with shorter
IDCM duration but not in patients with longer duration,
he association of treatment assignment with outcome was
ot significantly different in the two NIDCM duration
roups as indicated by the nonsignificant interaction term
p  0.17 and 0.25 at three- and nine-month cut points,
espectively).
Adjusting for covariates that were different between
atients with recently and remotely diagnosed cardiomyop-
thy did not substantially alter the findings of the unad-
usted model. The hazard ratios for the effect of ICD
herapy were still not significant in patients with longer
IDCM diagnosis times (HR 0.80; 95% CI 0.46 to 1.41;
 0.44 and HR 0.86; 95% CI 0.46 to 1.61; p  0.63 at
hree- and nine-month cut points). After adjustment, the
azard ratio for ICD treatment became significant in the
ecently diagnosed group at the nine-month cut point (HR
.46; 95% CI 0.216 to 0.986; p  0.046), and it remained
Remotely Diagnosed Cardiomyopathy: 3- and 9-Month
n  308 <9 Mo; n  216 >9 Mo; n  242
% n % n %
47.7 120 55.6 109 * 45.0
70.5 153 70.8 173 71.5
64.0 162 75.0 147* 60.7
26.3 44 20.4 68 28.1
20.5 55 25.5 44* 18.2
57.1 122 56.5 141 58.3
21.0 39 18.1 57 23.6
27.6 35 16.2 70* 28.9
12.0 21 9.7 28 11.6
84.4 189 87.5 200 82.6
94.5 206 95.4 227 93.8
SD Mean SD Mean SD
12.8 57.8 13.4 58.7 12.5
28.9 111.2 27.8 118.6* 29.1
6.2 21.0 5.4 21.7 6.5
eptor blocker; ICD implantable cardioverter-defibrillator; LVEF left ventricular
y Diagnosed Cardiomyopathy: 3- and 9-Month Cut Points
08 <9 Mo; n  216 >9 Mo; n  242
% n % n %
16.2 28/216 13.0 40/242 16.5
17.4 17/96 17.7 23/133 17.3
15.0 11/120 9.2 17/109 15.6and
Mo;otel
n  3ression test.
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ICD After Nonischemic Cardiomyopathy Diagnosis June 20, 2006:2477–82nchanged for the same comparison with the three-month
utoff (HR 0.38; 95% CI 0.14 to 1.000; p  0.050). As
efore adjustment, the impact of treatment did not signif-
cantly differ among patients with shorter and longer
IDCM diagnosis durations (p  0.186 and 0.22 at three-
nd nine-month cut points, respectively). The outcomes
ere also generally similar when we used a subset of
ovariates that were prespecified in the original DEFINITE
tudy; namely, gender, age, left ventricular ejection fraction,
nd NYHA functional class. The only notable difference,
gain, occurred in the analysis of the data with the nine-
onth split—the ICD benefit in the recently diagnosed
ohort, which only showed trend levels in the original
nalysis, was now significant (HR 0.43; 95% CI 0.20 to
.093; p  0.032).
igure 1. Kaplan-Meier estimates of death from any cause by treatmen
NIDCM) duration or less (A) and patients with more than three monthigure 2. Kaplan-Meier estimates of death from any cause by treatment arm
NIDCM) duration or less (A) and patients with more than nine months of NISCUSSION
he primary finding of the present study is that patients
ho have a recent cardiomyopathy diagnosis do not have
ny less ICD benefit than those with a remote diagnosis.
his result would not necessarily be expected because
atients with recently diagnosed cardiomyopathy could
otentially have reversible causes of left ventricular dysfunc-
ion and might be expected to have a lower risk of death.
atients with a clinical picture consistent with a reversible
ause such as myocarditis, tachycardia-induced cardiomy-
pathy, or peripartum cardiomyopathy were excluded from
andomization in the DEFINITE trial. Of patients who
ere randomized, whether the definition of recent diagnosis
as set at three or nine months, those patients with more
in patients with three months of nonischemic dilated cardiomyopathy
IDCM duration (B). ICD  implantable cardioverter-defibrillator.in patients with nine months of nonischemic dilated cardiomyopathy
IDCM duration (B). ICD  implantable cardioverter-defibrillator.
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June 20, 2006:2477–82 ICD After Nonischemic Cardiomyopathy Diagnosisecently diagnosed nonischemic cardiomyopathy had a sig-
ificant benefit from the ICD when appropriate clinical
ovariates were controlled. The ICD benefit in the recently
iagnosed group was not caused by death soon after ran-
omization because the survival curves continue to diverge
hroughout the entire trial period. Although the ICD was
elated to significantly improved survival in patients with
ecently diagnosed cardiomyopathy but not in those with
ardiomyopathy of a longer duration, the relative difference
etween the recent and remotely diagnosed groups for ICD
enefit was not significant. Thus, based on these results, one
annot conclude that there is a difference in ICD benefit
ased on the duration of nonischemic cardiomyopathy.
The natural history of nonischemic cardiomyopathy is vari-
ble. The evolution and prognosis of the disease may be
etermined by the underlying cause of the cardiomyopathy. In
ne series of 1,230 patients referred for evaluation of unex-
lained cardiomyopathy, the etiology was found to be idio-
athic (50%), myocarditis (9%), infiltrative myocardial disease,
ypertension, human immunodeficiency virus, peripartum car-
iomyopathy, connective tissue disease, substance abuse,
oxorubicin-induced, and other causes (all 5%) (1). This
eries was published before the results of the more recent
tudies became available, suggesting that genetic disorders were
common cause of nonischemic cardiomyopathy (9). The
atients randomized in the DEFINITE trial had a variety of
tiologies of nonischemic cardiomyopathy, but the majority
as classified as idiopathic. Perhaps a task force of heart failure
xperts should be established to develop a reliable list of
eversible myopathic processes (myocarditis, severe obstructive
utflow tract disease, paroxysmal atrial fibrillation, frequent
entricular ectopy, and so on) before a more aggressive ap-
roach to defibrillator implantation is considered in this patient
opulation.
In the present study, patients with more recently diag-
osed nonischemic cardiomyopathy had a similar survival
ompared with those with NIDCM of a longer duration.
he ICD benefit seemed at least as prominent in those with
ecently diagnosed cardiomyopathy. One possible explana-
ion is that as the duration of heart failure increases, the
ercentage of deaths caused by nonarrhythmic causes in-
rease, leading to a less apparent ICD benefit.
In a prior analysis, using the time from diagnosis of
ardiomyopathy to randomization did not significantly af-
ect ICD benefit when it was used as a continuous variable
n a covariate analysis (4). This conclusion is similar to that
rawn from the nonsignificant interaction term between the
ime to diagnosis and ICD benefit. However, the trend
oward a greater ICD benefit in those patients with recently
iagnosed cardiomyopathy was accentuated by the dichot-
mous analysis. There is biological plausibility to dichoto-
izing this parameter. The time immediately after the
evelopment of cardiomyopathy may be a time when the
isease process and consequent remodeling are in rapid
volution, and this process may stabilize after some time.
ardiomyopathy of 10 years’ duration may be no different in cisk from that of 2 years, yet a continuous variable analysis
ould seek to assign highly different risk values to these
ime points.
There were some differences in baseline characteristics
etween patients with recently and remotely diagnosed
ardiomyopathy. Although the differences that reached
tatistical significance changed depending on which cut
oint was used (Table 1), in the case of NYHA functional
lass, in general, patients with remotely diagnosed cardio-
yopathy had a longer QRS duration and a lower percent-
ge of patients with NYHA class I heart failure. These
ifferences might be expected in patients with a longer
uration of heart failure. Patients with remotely diagnosed
ardiomyopathy were more likely to have diabetes and were
ore likely to be nonwhite. These differences likely oc-
urred by chance. Correcting for demographic differences
etween the two groups did not substantially alter the
azard ratio for ICD benefit for either the recently or the
emotely diagnosed groups.
rior studies. Three prior trials have examined the survival
enefit of ICDs for the primary prevention of sudden death
n nonischemic cardiomyopathy (7,10,11). Two meta-
nalyses have examined the use of ICDs for the secondary
revention of sudden death in patients with nonischemic
ardiomyopathy (12,13). No prior studies have specifically
xamined whether ICD benefit varies depending on the
ime from diagnosis of cardiomyopathy to randomization.
tudy limitations. The DEFINITE trial was not powered
o examine the time from diagnosis of nonischemic cardio-
yopathy to randomization, and the results of post-hoc
tudies should be interpreted with caution; however, the
nding that patients with recently diagnosed cardiomyopa-
hy benefited from ICD insertion did not significantly
hange after adjusting for covariates adds to the strength of
hese observations. There was a difference in the time from
iagnosis of cardiomyopathy to randomization between the
CD and standard therapy groups, and somewhat different
umbers of patients were randomized to each treatment
ssignment in recently and remotely diagnosed groups
Table 1). However, the Cox regression analysis does not
equire equal sample sizes, and thus the results of the
nalysis should be valid.
Although the main report of the DEFINITE trial sug-
ested a 35% decrease in mortality with ICD therapy, these
esults did not reach significance. Therefore, the lack of a
ignificant effect in some of the subgroups is not unexpected
nd cannot provide definite conclusions. However, a recent
eta-analysis has shown the ICD to decrease mortality in
IDCM, and the subgroup findings in the present study
lso suggest that patients with recently diagnosed NIDCM
ay benefit from ICD insertion (12).
onclusions. The risk of death seems high in patients with
recent diagnosis of cardiomyopathy, and ICD implanta-
ion seems to reduce this risk. Thus, if the ICD does provide
enefit by improving survival in patients with nonischemic
ardiomyopathy, as suggested by recent trials (12), ICD
t
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ICD After Nonischemic Cardiomyopathy Diagnosis June 20, 2006:2477–82herapy may be appropriate in such patients as soon as they
re identified and reversible left ventricular dysfunction is
xcluded.
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